Ferroptosis in Pulmonary Disease and Lung Cancer: Molecular Mechanisms, Crosstalk Regulation, and Therapeutic Strategies

Abstract

Ferroptosis is a distinct form of iron-dependent programmed cell death characterized primarily by intracellular iron accumulation and lipid peroxidation. Multiple cellular processes, including amino acid metabolism, iron metabolism, lipid metabolism, various signaling pathways, and autophagy, have been demonstrated to influence the induction and progression of ferroptosis. Recent investigations have elucidated that ferroptosis plays a crucial role in the pathogenesis of various pulmonary disorders, including lung injury, chronic obstructive pulmonary disease, pulmonary fibrosis, and asthma. Ferroptosis is increasingly recognized as a promising novel strategy for cancer treatment. Various immune cells within the tumor microenvironment, including CD8+ T cells, macrophages, regulatory T cells, natural killer cells, and dendritic cells, have been shown to induce ferroptosis in tumor cells and modulate the process through the regulation of iron and lipid metabolism pathways. Conversely, ferroptosis can reciprocally alter the metabolic environment, leading to the activation or inhibition of immune cell functions, thereby modulating immune responses. This paper reviews the molecular mechanism of ferroptosis and describes the tumor immune microenvironment, discusses the connection between ferroptosis and the tumor microenvironment in lung cancer and pulmonary diseases, and discusses the development prospect of their interaction in the treatment of lung cancer and pulmonary diseases.

Keywords

ferroptosis / immune microenvironment / lung cancer / molecular mechanisms / pulmonary disease

References

[1] Y. Mou, J. Wang, J. Wu, et al., “Ferroptosis, a New Form of Cell Death: Opportunities and Challenges in Cancer,” Journal of Hematology & Oncology 12, no. 1 (2019): 34.

[2] D. Tang, X. Chen, R. Kang, and G. Kroemer, “Ferroptosis: Molecular Mechanisms and Health Implications,” Cell Research 31, no. 2 (2021): 107–125.

[3] J. Li, F. Cao, H. L. Yin, et al., “Ferroptosis: Past, Present and Future,” Cell Death & Disease 11, no. 2 (2020): 88.

[4] H. Yuan, J. Pratte, and C. Giardina, “Ferroptosis and Its Potential as a Therapeutic Target,” Biochemical Pharmacology 186 (2021): 114486.

[5] X. Chen, R. Kang, G. Kroemer, and D. Tang, “Organelle-specific Regulation of Ferroptosis,” Cell Death and Differentiation 28, no. 10 (2021): 2843–2856.

[6] D. Bertheloot, E. Latz, and B. S. Franklin, “Necroptosis, Pyroptosis and Apoptosis: An Intricate Game of Cell Death,” Cell Mol Immunol 18, no. 5 (2021): 1106–1121.

[7] S. Wang, S. Guo, J. Guo, et al., “Cell Death Pathways: Molecular Mechanisms and Therapeutic Targets for Cancer,” Med Comm (2020) 5, no. 9 (2024): e693.

[8] M. Kist and D. Vucic, “Cell Death Pathways: Intricate Connections and Disease Implications,” Embo Journal 40, no. 5 (2021): e106700.

[9] C. Zhang and N. Liu, “Ferroptosis, Necroptosis, and Pyroptosis in the Occurrence and Development of Ovarian Cancer,” Frontiers in Immunology 13 (2022): 920059.

[10] X. Tong, R. Tang, X. M., et al., “Targeting Cell Death Pathways for Cancer Therapy: Recent Developments in Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis Research,” Journal of Hematology & Oncology 15, no. 1 (2022).

[11] J. Liu, R. Kang, and D. Tang, “Signaling Pathways and Defense Mechanisms of Ferroptosis,” Febs Journal 289, no. 22 (2022): 7038–7050.

[12] D. Liang, A. M. Minikes, and X. Jiang, “Ferroptosis at the Intersection of Lipid Metabolism and Cellular Signaling,” Molecular Cell 82, no. 12 (2022).

[13] M. Binnewies, E. W. Roberts, K. Kersten, et al., “Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy,” Nature Medicine 24, no. 5 (2018): 541–550.

[14] S. Li and Y. Huang, “Ferroptosis: An Iron-dependent Cell Death Form Linking Metabolism, Diseases, Immune Cell and Targeted Therapy,” Clinical & Translational Oncology 24, no. 1 (2022): 1–12.

[15] W. Zhu, X. Liu, L. Yang, Q. He, D. Huang, and X. Tan, “Ferroptosis and Tumor Immunity: In Perspective of the Major Cell Components in the Tumor Microenvironment,” European Journal of Pharmacology 961 (2023): 176124.

[16] L. Yu, Y. Qiu, and X. Tong, “Ferroptosis in Renal Cancer Therapy: A Narrative Review of Drug Candidates,” Cancers (Basel) 16, no. 18 (2024): 3131.

[17] D. Li, Y. Wang, C. Dong, et al., “CST1 inhibits Ferroptosis and Promotes Gastric Cancer Metastasis by Regulating GPX4 Protein Stability via OTUB1,” Oncogene 42, no. 2 (2023): 83–98.

[18] L. Mahoney-Sánchez, H. Bouchaoui, S. Ayton, D. Devos, J. A. Duce, and J. C. Devedjian, “Ferroptosis and Its Potential Role in the Physiopathology of Parkinson’s Disease,” Progress in Neurobiology 196 (2021): 101890.

[19] S. K. Ryan, M. Zelic, Y. Han, et al., “Microglia Ferroptosis Is Regulated by SEC24B and Contributes to Neurodegeneration,” Nature Neuroscience 26, no. 1 (2023): 12–26.

[20] L. Huo, C. Liu, Y. Yuan, X. Liu, and Q. Cao, “Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Sepsis-associated Organ Damage,” European Journal of Medicinal Chemistry 257 (2023): 115438.

[21] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, et al., “Ferroptosis: An Iron-dependent Form of Nonapoptotic Cell Death,” Cell 149, no. 5 (2012): 1060–1072.

[22] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir, et al., “Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease,” Cell 171, no. 2 (2017): 273–285.

[23] M. R. Liu, W. T. Zhu, and D. S. Pei, “System Xc-: A Key Regulatory Target of Ferroptosis in Cancer,” Investigational New Drugs 39, no. 4 (2021): 1123–1131.

[24] F. J. Li, H. Z. Long, Z. W. Zhou, H. Y. Luo, S. G. Xu, and L. C. Gao, “System Xc -/GSH/GPX4 Axis: An Important Antioxidant System for the Ferroptosis in Drug-resistant Solid Tumor Therapy,” Frontiers in Pharmacology 13 (2022): 910292.

[25] S. J. Dixon, D. N. Patel, M. Welsch, et al., “Pharmacological Inhibition of Cystine-glutamate Exchange Induces Endoplasmic Reticulum Stress and Ferroptosis,” Elife 3 (2014): e02523.

[26] M. Gao, P. Monian, N. Quadri, R. Ramasamy, and X. Jiang, “Glutaminolysis and Transferrin Regulate Ferroptosis,” Molecular Cell 59, no. 2 (2015): 298–308.

[27] J. Lee and J. L. Roh, “SLC7A11 as a Gateway of Metabolic Perturbation and Ferroptosis Vulnerability in Cancer,” Antioxidants (Basel) 11, no. 12 (2022): 2444.

[28] M. A. Badgley, D. M. Kremer, H. C. Maurer, et al., “Cysteine Depletion Induces Pancreatic Tumor Ferroptosis in Mice,” Science 368, no. 6486 (2020): 85–89.

[29] G. C. Forcina and S. J. Dixon, “GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis,” Proteomics 19, no. 18 (2019): e1800311.

[30] L. Wang, Y. Liu, T. Du, et al., “ATF3 promotes Erastin-induced Ferroptosis by Suppressing System Xc,” Cell Death and Differentiation 27, no. 2 (2020): 662–675.

[31] W. S. Yang and B. R. Stockwell, “Ferroptosis: Death by Lipid Peroxidation,” Trends in Cell Biology 26, no. 3 (2016): 165–176.

[32] F. Ursini and M. Maiorino, “Lipid Peroxidation and Ferroptosis: The Role of GSH and GPx4,” Free Radic Biol Med 152 (2020): 175–185.

[33] B. Gan, “ACSL4, PUFA, and Ferroptosis: New Arsenal in Anti-tumor Immunity,” Signal Transduct Target Ther 7, no. 1 (2022): 128.

[34] M. S. Mortensen, J. Ruiz, and J. L. Watts, “Polyunsaturated Fatty Acids Drive Lipid Peroxidation during Ferroptosis,” Cells 12, no. 5 (2023): 804.

[35] V. E. Kagan, G. Mao, F. Qu, et al., “Oxidized Arachidonic and Adrenic PEs Navigate Cells to Ferroptosis,” Nature Chemical Biology 13, no. 1 (2017): 81–90.

[36] Z. Lin, J. Liu, R. Kang, M. Yang, and D. Tang, “Lipid Metabolism in Ferroptosis,” Adv Biol (Weinh) 5, no. 8 (2021): e2100396.

[37] J. Y. Lee, W. K. Kim, K. H. Bae, S. C. Lee, and E. W. Lee, “Lipid Metabolism and Ferroptosis,” Biology (Basel) 10, no. 3 (2021): 184.

[38] S. Doll, B. Proneth, Y. Y. Tyurina, et al., “ACSL4 dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition,” Nature Chemical Biology 13, no. 1 (2017): 91–98.

[39] A. Reed, T. A. Ichu, N. Milosevich, et al., “LPCAT3 Inhibitors Remodel the Polyunsaturated Phospholipid Content of Human Cells and Protect from Ferroptosis,” Acs Chemical Biology 17, no. 6 (2022): 1607–1618.

[40] S. J. Dixon and B. R. Stockwell, “The Role of Iron and Reactive Oxygen Species in Cell Death,” Nature Chemical Biology 10, no. 1 (2014): 9–17.

[41] N. Tao, K. Li, and J. Liu, “Molecular Mechanisms of Ferroptosis and Its Role in Pulmonary Disease,” Oxid Med Cell Longev 2020 (2020): 9547127.

[42] Z. Shen, T. Liu, Y. Li, et al., “Fenton-Reaction-Acceleratable Magnetic Nanoparticles for Ferroptosis Therapy of Orthotopic Brain Tumors,” ACS Nano 12, no. 11 (2018): 11355–11365.

[43] Y. J. He, X. Y. Liu, L. Xing, X. Wan, X. Chang, and H. L. Jiang, “Fenton Reaction-independent Ferroptosis Therapy via Glutathione and Iron Redox Couple Sequentially Triggered Lipid Peroxide Generator,” Biomaterials 241 (2020): 119911.

[44] L. Rochette, G. Dogon, E. Rigal, M. Zeller, Y. Cottin, and C. Vergely, “Lipid Peroxidation and Iron Metabolism: Two Corner Stones in the Homeostasis Control of Ferroptosis,” International Journal of Molecular Sciences 24, no. 1 (2022): 449.

[45] Y. Xie, Y. Zhou, J. Wang, L. Du, Y. Ren, and F. Liu, “Ferroptosis, Autophagy, Tumor and Immunity,” Heliyon 9, no. 9 (2023): e19799.

[46] B. Zhou, J. Liu, R. Kang, D. J. Klionsky, G. Kroemer, and D. Tang, “Ferroptosis Is a Type of Autophagy-Dependent Cell Death,” Seminars in Cancer Biology 66 (2020): 89–100.

[47] M. Gryzik, M. Asperti, A. Denardo, P. Arosio, and M. Poli, “NCOA4-Mediated Ferritinophagy Promotes Ferroptosis Induced by Erastin, but Not by RSL3 in HeLa Cells,” Biochimica Et Biophysica Acta (BBA)—Molecular Cell Research 1868, no. 2 (2021): 118913.

[48] N. Santana-Codina and J. D. Mancias, “The Role of NCOA4-Mediated Ferritinophagy in Health and Disease,” Pharmaceuticals (Basel) 11, no. 4 (2018): 114.

[49] M. Gao, P. Monian, Q. Pan, W. Zhang, J. Xiang, and X. Jiang, “Ferroptosis Is an Autophagic Cell Death Process,” Cell Research 26, no. 9 (2016): 1021–1032.

[50] E. Park and S. W. Chung, “ROS-mediated Autophagy Increases Intracellular Iron Levels and Ferroptosis by Ferritin and Transferrin Receptor Regulation,” Cell Death & Disease 10, no. 11 (2019): 822.

[51] B. Wang, Y. Wang, J. Zhang, et al., “ROS-induced Lipid Peroxidation Modulates Cell Death Outcome: Mechanisms behind Apoptosis, Autophagy, and Ferroptosis,” Archives of Toxicology 97, no. 6 (2023): 1439–1451.

[52] S. Arakawa, S. Honda, H. Yamaguchi, and S. Shimizu. Molecular Mechanisms and Physiological Roles of Atg5/Atg7-Independent Alternative Autophagy. Proceedings of the Japan Academy, Series B 2017; 93(6): 378–385.

[53] W. Hou, Y. Xie, X. Song, et al., “Autophagy Promotes Ferroptosis by Degradation of Ferritin,” Autophagy 12, no. 8 (2016): 1425–1428.

[54] Y. Li, Y. Du, Y. Zhou, et al., “Iron and Copper: Critical Executioners of Ferroptosis, Cuproptosis and Other Forms of Cell Death,” Cell Communication and Signaling 21, no. 1 (2023): 327.

[55] B. R. Stockwell, “Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications,” Cell 185, no. 14 (2022): 2401–2421.

[56] B. Niu, K. Liao, Y. Zhou, et al., “Application of Glutathione Depletion in Cancer Therapy: Enhanced ROS-based Therapy, Ferroptosis, and Chemotherapy,” Biomaterials 277 (2021): 121110.

[57] C. Chen, D. Wang, Y. Yu, et al., “Legumain Promotes Tubular Ferroptosis by Facilitating Chaperone-mediated Autophagy of GPX4 in AKI,” Cell Death & Disease 12, no. 1 (2021): 65.

[58] C. C. Lin, W. H. Yang, Y. T. Lin, et al., “DDR2 upregulation Confers Ferroptosis Susceptibility of Recurrent Breast Tumors through the Hippo Pathway,” Oncogene 40, no. 11 (2021): 2018–2034.

[59] M. J. Hangauer, V. S. Viswanathan, M. J. Ryan, et al., “Drug-tolerant Persister Cancer Cells Are Vulnerable to GPX4 Inhibition,” Nature 551, no. 7679 (2017): 247–250.

[60] G. Lei, L. Zhuang, and B. Gan, “The Roles of Ferroptosis in Cancer: Tumor Suppression, Tumor Microenvironment, and Therapeutic Interventions,” Cancer Cell 42, no. 4 (2024): 513–534.

[61] Y. Zheng, L. Sun, J. Guo, and J. Ma, “The Crosstalk between Ferroptosis and Anti-tumor Immunity in the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Controversy,” Cancer Commun (Lond) 43, no. 10 (2023): 1071–1096.

[62] Q. Bi, Z. J. Sun, J. Y. Wu, and W. Wang, “Ferroptosis-Mediated Formation of Tumor-Promoting Immune Microenvironment,” Frontiers in Oncology 12 (2022).

[63] J. Liu, M. Hong, Y. Li, D. Chen, Y. Wu, and Y. Hu, “Programmed Cell Death Tunes Tumor Immunity,” Frontiers in Immunology 13 (2022): 847345.

[64] G. Sy, L. Swl, S. Jl, and W. Sc, “Targeting Immune Cells for Cancer Therapy,” Redox Biology (2019): 25.

[65] J. Park, P. C. Hsueh, Z. Li, and P. C. Ho, “Microenvironment-Driven Metabolic Adaptations Guiding CD8+ T Cell Anti-Tumor Immunity,” Immunity 56, no. 1 (2023): 32–42.

[66] D. C. Hinshaw and L. A. Shevde, “The Tumor Microenvironment Innately Modulates Cancer Progression,” Cancer Research 79, no. 18 (2019): 4557–4566.

[67] K. Cui, K. Wang, and Z. Huang, “Ferroptosis and the Tumor Microenvironment,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 315.

[68] P. Wang and Y. Q. Lu, “Ferroptosis: A Critical Moderator in the Life Cycle of Immune Cells,” Frontiers in Immunology 13 (2022): 877634.

[69] C. Gong, Q. Ji, M. Wu, et al., “Ferroptosis in Tumor Immunity and Therapy,” Journal of Cellular and Molecular Medicine 26, no. 22 (2022): 5565–5579.

[70] H. Xu, D. Ye, M. Ren, H. Zhang, and F. Bi, “Ferroptosis in the Tumor Microenvironment: Perspectives for Immunotherapy,” Trends in Molecular Medicine 27, no. 9 (2021): 856–867.

[71] R. Kim, D. Taylor, R. H. Vonderheide, and D. I. Gabrilovich, “Ferroptosis of Immune Cells in the Tumor Microenvironment,” Trends in Pharmacological Sciences 44, no. 8 (2023): 542–552.

[72] R. Kong, N. Wang, W. Han, W. Bao, and J. Lu, “IFNγ-mediated Repression of System Xc-drives Vulnerability to Induced Ferroptosis in Hepatocellular Carcinoma Cells,” J Leukoc Biol 110, no. 2 (2021): 301–314.

[73] W. Wang, M. Green, J. E. Choi, et al., “CD8+ T Cells Regulate Tumour Ferroptosis during Cancer Immunotherapy,” Nature 569, no. 7755 (2019): 270–274.

[74] X. Lang, M. D. Green, W. Wang, et al., “Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11,” Cancer Discovery 9, no. 12 (2019): 1673–1685.

[75] P. Liao, W. Wang, W. Wang, et al., “CD8+ T Cells and Fatty Acids Orchestrate Tumor Ferroptosis and Immunity via ACSL4,” Cancer Cell 40, no. 4 (2022): 365–378.

[76] X. Ma, L. Xiao, L. Liu, et al., “CD36-mediated Ferroptosis Dampens Intratumoral CD8+ T Cell Effector Function and Impairs Their Antitumor Ability,” Cell Metabolism 33, no. 5 (2021): 1001–1012.

[77] S. Xu, O. Chaudhary, P. Rodríguez-Morales, et al., “Uptake of Oxidized Lipids by the Scavenger Receptor CD36 Promotes Lipid Peroxidation and Dysfunction in CD8+ T Cells in Tumors,” Immunity 54, no. 7 (2021): 1561–1577.

[78] A new thiol-independent mechanism of epithelial host defense against Pseudomonas aeruginosa: iNOS/NO• sabotage of theft-ferroptosis—PubMed.

[79] A. A. Kapralov, Q. Yang, H. H. Dar, et al., “Redox Lipid Reprogramming Commands Susceptibility of Macrophages and Microglia to Ferroptotic Death,” Nature Chemical Biology 16, no. 3 (2020): 278–290.

[80] X. Hao, Z. Zheng, H. Liu, et al., “Inhibition of APOC1 Promotes the Transformation of M2 into M1 Macrophages via the Ferroptosis Pathway and Enhances Anti-PD1 Immunotherapy in Hepatocellular Carcinoma Based on Single-cell RNA Sequencing,” Redox Biology 56 (2022): 102463.

[81] C. Xu, S. Sun, T. Johnson, et al., “The Glutathione Peroxidase Gpx4 Prevents Lipid Peroxidation and Ferroptosis to Sustain Treg Cell Activation and Suppression of Antitumor Immunity,” Cell Reports 35, no. 11 (2021): 109235.

[82] S. M. Poznanski, K. Singh, T. M. Ritchie, et al., “Metabolic Flexibility Determines human NK Cell Functional Fate in the Tumor Microenvironment,” Cell Metabolism 33, no. 6 (2021): 1205–1220.

[83] L. Han, L. Bai, C. Qu, et al., “PPARG-mediated Ferroptosis in Dendritic Cells Limits Antitumor Immunity,” Biochemical and Biophysical Research Communications 576 (2021): 33–39.

[84] W. Lan, L. Yang, and X. Tan, “Crosstalk between Ferroptosis and Macrophages: Potential Value for Targeted Treatment in Diseases,” Molecular and Cellular Biochemistry (2023). Published online. October 25.

[85] Y. Yang, Y. Wang, L. Guo, W. Gao, T. L. Tang, and M. Yan, “Interaction between Macrophages and Ferroptosis,” Cell Death & Disease 13, no. 4 (2022): 355.

[86] J. H. Kang and R. Zappasodi, “Modulating Treg Stability to Improve Cancer Immunotherapy,” Trends in Cancer 9, no. 11 (2023): 911–927.

[87] D. Sugiyama, K. Hinohara, and H. Nishikawa, “Significance of Regulatory T Cells in Cancer Immunology and Immunotherapy,” Experimental Dermatology 32, no. 3 (2023): 256–263.

[88] M. G. Morvan and L. L. Lanier, “NK Cells and Cancer: You Can Teach Innate Cells New Tricks,” Nature Reviews Cancer 16, no. 1 (2016): 7–19.

[89] J. Banchereau, F. Briere, C. Caux, et al., “Immunobiology of Dendritic Cells,” Annual Review of Immunology 18 (2000): 767–811.

[90] A. Waisman, D. Lukas, B. E. Clausen, and N. Yogev, “Dendritic Cells as Gatekeepers of Tolerance,” Seminars in Immunopathology 39, no. 2 (2017): 153–163.

[91] D. L. Herber, W. Cao, Y. Nefedova, et al., “Lipid Accumulation and Dendritic Cell Dysfunction in Cancer,” Nature Medicine 16, no. 8 (2010): 880–886.

[92] B. Wiernicki, S. Maschalidi, J. Pinney, et al., “Cancer Cells Dying from Ferroptosis Impede Dendritic Cell-mediated Anti-tumor Immunity,” Nature Communications 13, no. 1 (2022): 3676.

[93] R. Ramakrishnan, V. A. Tyurin, F. Veglia, et al., “Oxidized Lipids Block Antigen Cross-presentation by Dendritic Cells in Cancer,” Journal of Immunology 192, no. 6 (2014): 2920–2931.

[94] H. Zhang, T. Deng, R. Liu, et al., “CAF Secreted miR-522 Suppresses Ferroptosis and Promotes Acquired Chemo-resistance in Gastric Cancer,” Molecular Cancer 19, no. 1 (2020): 43.

[95] Y. Li, Z. Ma, W. Li, et al., “PDPN+ CAFs Facilitate the Motility of OSCC Cells by Inhibiting Ferroptosis via Transferring Exosomal lncRNA FTX,” Cell Death & Disease 14, no. 11 (2023): 759.

[96] R. Qi, Y. Bai, K. Li, et al., “Cancer-associated Fibroblasts Suppress Ferroptosis and Induce Gemcitabine Resistance in Pancreatic Cancer Cells by Secreting Exosome-derived ACSL4-targeting miRNAs,” Drug Resistance Updates 68 (2023): 100960.

[97] Y. Zhu, S. Fang, B. Fan, et al., “Cancer-associated Fibroblasts Reprogram Cysteine Metabolism to Increase Tumor Resistance to Ferroptosis in Pancreatic Cancer,” Theranostics 14, no. 4 (2024): 1683–1700.

[98] Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation—PubMed.

[99] X. Chen, R. Kang, G. Kroemer, and D. Tang, “Broadening Horizons: The Role of Ferroptosis in Cancer,” Nature Reviews Clinical Oncology 18, no. 5 (2021): 280–296.

[100] J. Wu, L. Ma, J. Wang, and Y. Qiao, “[Mechanism of Ferroptosis and Its Research Progress in Lung Cancer],” Zhongguo Fei Ai Za Zhi 23, no. 9 (2020): 811–817.

[101] D. Wang, X. Li, D. Jiao, et al., “LCN2 secreted by Tissue-infiltrating Neutrophils Induces the Ferroptosis and Wasting of Adipose and Muscle Tissues in Lung Cancer Cachexia,” Journal of Hematology & Oncology 16, no. 1 (2023): 30.

[102] L. Yang, L. M. Cao, X. J. Zhang, and B. Chu, “Targeting Ferroptosis as a Vulnerability in Pulmonary Diseases,” Cell Death & Disease 13, no. 7 (2022): 649.

[103] S. Yu, J. Jia, J. Zheng, Y. Zhou, D. Jia, and J. Wang, “Recent Progress of Ferroptosis in Lung Diseases,” Frontiers in Cell and Developmental Biology 9 (2021): 789517.

[104] J. Zhang, Y. Zheng, Y. Wang, et al., “YAP1 alleviates Sepsis-induced Acute Lung Injury via Inhibiting Ferritinophagy-mediated Ferroptosis,” Frontiers in Immunology 13 (2022).

[105] C. Bao, C. Liu, Q. Liu, et al., “Liproxstatin-1 Alleviates LPS/IL-13-induced Bronchial Epithelial Cell Injury and Neutrophilic Asthma in Mice by Inhibiting Ferroptosis,” International Immunopharmacology 109 (2022): 108770.

[106] X. Liu, J. Zhang, and W. Xie, “The Role of Ferroptosis in Acute Lung Injury,” Molecular and Cellular Biochemistry 477, no. 5 (2022): 1453–1461.

[107] X. Liu, L. Wang, Q. Xing, et al., “Sevoflurane Inhibits Ferroptosis: A New Mechanism to Explain Its Protective Role against Lipopolysaccharide-induced Acute Lung Injury,” Life Sciences 275 (2021): 119391.

[108] W. Xie, Q. Lu, K. Wang, et al., “miR-34b-5p Inhibition Attenuates Lung Inflammation and Apoptosis in an LPS-induced Acute Lung Injury Mouse Model by Targeting Progranulin,” Journal of Cellular Physiology 233, no. 9 (2018): 6615–6631.

[109] Y. Butt, A. Kurdowska, and T. C. Allen, “Acute Lung Injury: A Clinical and Molecular Review,” Archives of Pathology & Laboratory Medicine 140, no. 4 (2016): 345–350.

[110] H. Dong, Z. Qiang, D. Chai, et al., “Nrf2 inhibits Ferroptosis and Protects against Acute Lung Injury due to Intestinal Ischemia Reperfusion via Regulating SLC7A11 and HO-1,” Aging (Albany NY) 12, no. 13 (2020): 12943–12959.

[111] T. Yu and S. Sun, “Role and Mechanism of Ferroptosis in Acute Lung Injury,” Cell Cycle 22, no. 19 (2023): 2119–2129.

[112] X. Dong, D. Li, Z. Fang, C. Zhang, J. Wang, and X. Wan, “Astaxanthin Alleviates Lipopolysaccharide-induced Acute Lung Injury by Suppressing Ferroptosis,” Food Funct 14, no. 13 (2023): 6115–6127.

[113] J. Li, K. Lu, F. Sun, et al., “Panaxydol Attenuates Ferroptosis against LPS-induced Acute Lung Injury in Mice by Keap1-Nrf2/HO-1 Pathway,” Journal of Translational Medicine 19, no. 1 (2021): 96.

[114] Y. Yang, Y. Ma, Q. Li, et al., “STAT6 inhibits Ferroptosis and Alleviates Acute Lung Injury via Regulating P53/SLC7A11 Pathway,” Cell Death & Disease 13, no. 6 (2022): 530.

[115] L. Jiang, N. Kon, T. Li, et al., “Ferroptosis as a p53-mediated Activity during Tumour Suppression,” Nature 520, no. 7545 (2015): 57–62.

[116] A. Tarangelo, L. Magtanong, K. T Bieging-Rolett, et al., “p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells,” Cell Reports 22, no. 3 (2018): 569–575.

[117] R. He, B. Liu, R. Xiong, et al., “Itaconate Inhibits Ferroptosis of Macrophage via Nrf2 Pathways against Sepsis-induced Acute Lung Injury,” Cell Death Discov 8, no. 1 (2022): 43.

[118] H. Hammad and B. N. Lambrecht, “The Basic Immunology of Asthma,” Cell 184, no. 6 (2021): 1469–1485.

[119] L. Liu, L. Zhou, L. L. Wang, et al., “Programmed Cell Death in Asthma: Apoptosis, Autophagy, Pyroptosis, Ferroptosis, and Necroptosis,” J Inflamm Res 16 (2023): 2727–2754.

[120] M. Li, M. Li, Y. Hou, et al., “Ferroptosis Triggers Airway Inflammation in Asthma,” Ther Adv Respir Dis 17 (2023): 17534666231208628.

[121] X. Lv, M. Dong, W. Tang, et al., “Ferroptosis, Novel Therapeutics in Asthma,” Biomedicine & Pharmacotherapy 153 (2022): 113516.

[122] W. Tang, M. Dong, F. Teng, et al., “Environmental Allergens House Dust Mite-Induced Asthma Is Associated With Ferroptosis in the Lungs,” Experimental and Therapeutic Medicine 22, no. 6 (2021): 1–10.

[123] R. Shah, M. S. Shchepinov, and D. A. Pratt, “Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis,” ACS Cent Sci 4, no. 3 (2018): 387–396.

[124] C. Liu, D. Xu, L. Liu, et al., “15-Lipoxygenase-1 Induces Expression and Release of Chemokines in Cultured human Lung Epithelial Cells,” American Journal of Physiology Lung Cellular and Molecular Physiology 297, no. 1 (2009): L196–203.

[125] W. S. Yang, K. J. Kim, M. M. Gaschler, M. Patel, M. S. Shchepinov, and B. R. Stockwell, “Peroxidation of Polyunsaturated Fatty Acids by Lipoxygenases Drives Ferroptosis,” PNAS 113, no. 34 (2016): E4966–4975.

[126] N. K. Singh and G. N. Rao, “Emerging Role of 12/15-Lipoxygenase (ALOX15) in human Pathologies,” Progress in Lipid Research 73 (2019): 28–45.

[127] S. E. Wenzel, Y. Y. Tyurina, J. Zhao, et al., “PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals,” Cell 171, no. 3 (2017): 628–641.

[128] H. Wang, Y. Jia, J. Gu, O. Chen, and S. Yue, “Ferroptosis-related Genes Are Involved in Asthma and Regulate the Immune Microenvironment,” Frontiers in Pharmacology 14 (2023): 1087557.

[129] M. Dembele, S. Tao, A. H. Massoud, et al., “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs,” Frontiers in Immunology 12 (2021): 634509.

[130] P. J. Barnes, P. G. J. Burney, E. K. Silverman, et al., “Chronic Obstructive Pulmonary Disease,” Nature Reviews Disease Primers 1 (2015): 15076.

[131] D. Meng, C. Zhu, R. Jia, Z. Li, W. Wang, and S. Song, “The Molecular Mechanism of Ferroptosis and Its Role in COPD,” Front Med (Lausanne) 9 (2022): 1052540.

[132] M. Yoshida, S. Minagawa, J. Araya, et al., “Involvement of Cigarette Smoke-induced Epithelial Cell Ferroptosis in COPD Pathogenesis,” Nature Communications 10, no. 1 (2019): 3145.

[133] J. Lu, Y. Zhao, M. Liu, J. Lu, and S. Guan, “Toward Improved human Health: Nrf2 Plays a Critical Role in Regulating Ferroptosis,” Food Funct 12, no. 20 (2021): 9583–9606.

[134] X. Liu, Y. Ma, L. Luo, et al., “Dihydroquercetin Suppresses Cigarette Smoke Induced Ferroptosis in the Pathogenesis of Chronic Obstructive Pulmonary Disease by Activating Nrf2-mediated Pathway,” Phytomedicine 96 (2022): 153894.

[135] J. Liu, Z. Zhang, Y. Yang, T. Di, Y. Wu, and T. Bian, “NCOA4-Mediated Ferroptosis in Bronchial Epithelial Cells Promotes Macrophage M2 Polarization in COPD Emphysema,” Int J Chron Obstruct Pulmon Dis 17 (2022): 667–681.

[136] N. Santana-Codina, A. Gikandi, and J. D. Mancias, “The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis,” Advances in Experimental Medicine and Biology 1301 (2021): 41–57.

[137] V. J. Thannickal, G. B. Toews, E. S. White, J. P. Lynch, and F. J. Martinez, “Mechanisms of Pulmonary Fibrosis,” Annual Review of Medicine 55 (2004): 395–417.

[138] T. Koudstaal, M. Funke-Chambour, M. Kreuter, P. L. Molyneaux, and M. S. Wijsenbeek, “Pulmonary Fibrosis: From Pathogenesis to Clinical Decision-making,” Trends in Molecular Medicine 29, no. 12 (2023): 1076–1087.

[139] D. Yue, Q. Zhang, J. Zhang, et al., “Diesel Exhaust PM2.5 Greatly Deteriorates Fibrosis Process in Pre-existing Pulmonary Fibrosis via Ferroptosis,” Environment International 171 (2023): 107706.

[140] H. Cheng, D. Feng, X. Li, et al., “Iron Deposition-induced Ferroptosis in Alveolar Type II Cells Promotes the Development of Pulmonary Fibrosis,” Biochim Biophys Acta Mol Basis Dis 1867, no. 12 (2021): 166204.

[141] M. Bocchino, S. Zanotta, L. Capitelli, and D. Galati, “Dendritic Cells Are the Intriguing Players in the Puzzle of Idiopathic Pulmonary Fibrosis Pathogenesis,” Frontiers in Immunology 12 (2021): 664109.

[142] Y. Liu, D. Cheng, Y. Wang, et al., “UHRF1-mediated Ferroptosis Promotes Pulmonary Fibrosis via Epigenetic Repression of GPX4 and FSP1 Genes,” Cell Death & Disease 13, no. 12 (2022): 1070.

[143] Z. Pei, Y. Qin, X. Fu, et al., “Inhibition of Ferroptosis and Iron Accumulation Alleviates Pulmonary Fibrosis in a Bleomycin Model,” Redox Biology 57 (2022): 102509.

[144] Y. Yang, W. Tai, N. Lu, et al., “lncRNA ZFAS1 Promotes Lung Fibroblast-to-myofibroblast Transition and Ferroptosis via Functioning as a ceRNA through miR-150-5p/SLC38A1 Axis,” Aging (Albany NY) 12, no. 10 (2020): 9085–9102.

[145] M. Zhang, M. Guo, Y. Gao, C. Wu, X. Pan, and Z. Huang, “Mechanisms and Therapeutic Targets of Ferroptosis: Implications for Nanomedicine Design,” Journal of Pharmaceutical Analysis 14, no. 7 (2024): 100960. Published online.

[146] M. Doroudian, A. O’ Neill, R. Mac Loughlin, A. Prina-Mello, Y. Volkov, and S. C. Donnelly, “Nanotechnology in Pulmonary Medicine,” Current Opinion in Pharmacology 56 (2021): 85–92.

[147] C. Y. Loo and W. H. Lee, “Nanotechnology-based Therapeutics for Targeting Inflammatory Lung Diseases,” Nanomedicine (Lond) 17, no. 12 (2022): 865–879.

[148] T. Liu, Q. Yang, H. Zheng, et al., “Multifaceted Roles of a Bioengineered Nanoreactor in Repressing Radiation-induced Lung Injury,” Biomaterials 277 (2021): 121103.

[149] T. M. Zacaron, M. Silva, M. P. Costa, et al., “Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery,” Polymers (Basel) 15, no. 18 (2023): 3849.

[150] M. Guo, T. Peng, C. Wu, X. Pan, and Z. Huang, “Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis,” Bioengineering (Basel) 10, no. 6 (2023): 727.

[151] D. Xiang, L. Zhou, R. Yang, et al., “Advances in Ferroptosis-Inducing Agents by Targeted Delivery System in Cancer Therapy,” Int J Nanomedicine 19 (2024): 2091–2112.

[152] E. Meunier and O. Neyrolles, “Die another Way: Ferroptosis Drives Tuberculosis Pathology,” Journal of Experimental Medicine 216, no. 3 (2019): 471–473.

[153] S. H. Kaufmann, “How Can Immunology Contribute to the Control of Tuberculosis?,” Nature Reviews Immunology 1, no. 1 (2001): 20–30.

[154] E. P. Amaral, D. L. Costa, S. Namasivayam, et al., “A Major Role for Ferroptosis in Mycobacterium Tuberculosis-induced Cell Death and Tissue Necrosis,” Journal of Experimental Medicine 216, no. 3 (2019): 556–570.

[155] M. Dai, W. Ouyang, Y. Yu, et al., “IFP35 aggravates Staphylococcus aureus Infection by Promoting Nrf2-regulated Ferroptosis,” Journal of Advanced Research, no. 23 (2023): S2090–1232. Published online September 29. 00291-6.

[156] Dihydroquercetin Attenuates Silica-Induced Pulmonary Fibrosis by Inhibiting Ferroptosis Signaling Pathway—PubMed.

[157] R. Bao, Q. Wang, M. Yu, et al., “AAV9-HGF Cooperating With TGF-beta/Smad Inhibitor Attenuates Silicosis Fibrosis via Inhibiting Ferroptosis,” Biomedicine & Pharmacotherapy 161 (2023): 114537.

[158] X. Wei, X. Li, S. Hu, J. Cheng, and R. Cai, “Regulation of Ferroptosis in Lung Adenocarcinoma,” International Journal of Molecular Sciences 24, no. 19 (2023): 14614.

[159] J. Zou, L. Wang, H. Tang, X. Liu, F. Peng, and C. Peng, “Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It,” International Journal of Molecular Sciences 22, no. 24 (2021): 13335.

[160] Y. Li, X. Li, and J. Li, “Ferroptosis in Lung Cancer: Dual Role, Multi-level Regulation, and New Therapeutic Strategies,” Frontiers in Oncology 14 (2024).

[161] N. Xing, Q. Du, S. Guo, et al., “Ferroptosis in Lung Cancer: A Novel Pathway Regulating Cell Death and a Promising Target for Drug Therapy,” Cell Death Discov 9, no. 1 (2023): 110.

[162] G. B. Gao, L. Chen, J. F. Pan, et al., “LncRNA RGMB-AS1 Inhibits HMOX1 Ubiquitination and NAA10 Activation to Induce Ferroptosis in Non-small Cell Lung Cancer,” Cancer Letters 590 (2024): 216826.

[163] Y. Xuan, K. Peng, R. Zhu, Y. Kang, and Z. Yin, “Hmox1 is Identified as a Ferroptosis Hub Gene and Associated With the M1 Type Microglia/Macrophage Polarization in Spinal Cord Injury: Bioinformatics and Experimental Validation,” Molecular Neurobiology 60, no. 12 (2023): 7151–7165.

[164] H. Cai, Y. Ren, S. Chen, Y. Wang, and L. Chu, “Ferroptosis and Tumor Immunotherapy: A Promising Combination Therapy for Tumors,” Frontiers in Oncology 13 (2023): 1119369.

[165] F. Yang, Y. Xiao, J. H. Ding, et al., “Ferroptosis Heterogeneity in Triple-negative Breast Cancer Reveals an Innovative Immunotherapy Combination Strategy,” Cell Metabolism 35, no. 1 (2023): 84–100.

[166] L. Ma, C. Chen, C. Zhao, et al., “Targeting Carnitine Palmitoyl Transferase 1A (CPT1A) Induces Ferroptosis and Synergizes With Immunotherapy in Lung Cancer,” Signal Transduction and Targeted Therapy 9, no. 1 (2024).

[167] C. Zhang, X. Liu, S. Jin, Y. Chen, and R. Guo, “Ferroptosis in Cancer Therapy: A Novel Approach to Reversing Drug Resistance,” Molecular Cancer 21, no. 1 (2022): 47.

[168] H. Zhou, X. Zhou, R. Zhu, et al., “A Ferroptosis-related Signature Predicts the Clinical Diagnosis and Prognosis, and Associates With the Immune Microenvironment of Lung Cancer,” Discov Oncol 15, no. 1 (2024): 163.

[169] D. Peng, M. Liang, L. Li, et al., “Circ_BBS9 as an Early Diagnostic Biomarker for Lung Adenocarcinoma: Direct Interaction With IFIT3 in the Modulation of Tumor Immune Microenvironment,” Frontiers in Immunology 15 (2024): 1344954.

[170] Y. Lu, X. Xie, and L. Luo, “Ferroptosis Crosstalk in Anti-tumor Immunotherapy: Molecular Mechanisms, Tumor Microenvironment, Application Prospects,” Apoptosis 29, no. 11-12 (2024): 1914–1943. Published online July 15.

[171] J. Lu, R. He, Y. Liu, et al., “Exploiting Cell Death and Tumor Immunity in Cancer Therapy: Challenges and Future Directions,” Frontiers in Cell and Developmental Biology 12 (2024): 1416115.

[172] C. Sun, J. Zhan, Y. Li, et al., “Non-apoptotic Regulated Cell Death Mediates Reprogramming of the Tumour Immune Microenvironment by Macrophages,” Journal of Cellular and Molecular Medicine 28, no. 8 (2024): e18348.

[173] Y. Li, H. Tuerxun, Y. Zhao, et al., “The New Era of Lung Cancer Therapy: Combining Immunotherapy With Ferroptosis,” Critical Reviews in Oncology/Hematology 198 (2024): 104359.

[174] Y. Huang, S. Wang, A. Ke, and K. Guo, “Ferroptosis and Its Interaction With Tumor Immune Microenvironment in Liver Cancer,” Biochim Biophys Acta Rev Cancer 1878, no. 1 (2023): 188848.

[175] T. Yun, Z. Liu, J. Wang, et al., “Microenvironment Immune Response Induced by Tumor Ferroptosis-the Application of Nanomedicine,” Frontiers in Oncology 12 (2022): 1019654.

[176] X. Chu, H. Y. Hou, M. D. Duan, et al., “Tumor Microenvironment Specific Regulation Ca-Fe-Nanospheres for Ferroptosis-Promoted Domino Synergistic Therapy and Tumor Immune Response,” Small 20, no. 40 (2024): e2312141.

[177] X. Shan, S. Li, B. Sun, et al., “Ferroptosis-driven Nanotherapeutics for Cancer Treatment,” J Control Release 319 (2020): 322–332.

[178] C. H. Hsieh, H. C. Hsieh, F. S. Shih, et al., “An Innovative NRF2 Nano-modulator Induces Lung Cancer Ferroptosis and Elicits an Immunostimulatory Tumor Microenvironment,” Theranostics 11, no. 14 (2021): 7072–7091.

[179] Z. Fan, S. Wu, H. Deng, G. Li, L. Huang, and H. Liu, “Light-Triggered Nanozymes Remodel the Tumor Hypoxic and Immunosuppressive Microenvironment for Ferroptosis-Enhanced Antitumor Immunity,” ACS Nano 18, no. 19 (2024): 12261–12275.

[180] H. E. S. El-Horany, M. M. Atef, M. T. Abdel Ghafar, et al., “Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2/AMPK/Nrf2 Signaling and Targeting Ferroptosis and Autophagy,” International Journal of Molecular Sciences 24, no. 11 (2023): 9481.

[181] N. Liang, W. Song, and J. Li, “BPA Promotes Lung Fibrosis in Mice by Regulating Autophagy-dependent Ferroptosis in Alveolar Epithelial Cells,” Ecotoxicol. Environ. Saf. 278 (2024): 116412.

[182] X. Wu, Y. Jiang, R. Li, et al., “Ficolin B Secreted by Alveolar Macrophage Exosomes Exacerbates Bleomycin-induced Lung Injury via Ferroptosis Through the cGAS-STING Signaling Pathway,” Cell Death & Disease 14, no. 8 (2023): 577.

[183] L. Li, D. Wu, S. Deng, et al., “NVP-AUY922 Alleviates Radiation-induced Lung Injury via Inhibition of Autophagy-dependent Ferroptosis,” Cell Death Discov 8, no. 1 (2022): 86.

[184] J. Du, L. Yu, X. Yang, et al., “Regulation of NCOA4-mediated Iron Recycling Ameliorates Paraquat-induced Lung Injury by Inhibiting Ferroptosis,” Cell Communication and Signaling 22, no. 1 (2024): 146.

[185] V. Bhatt, T. Lan, W. Wang, et al., “Inhibition of Autophagy and MEK Promotes Ferroptosis in Lkb1-deficient Kras-driven Lung Tumors,” Cell Death & Disease 14, no. 1 (2023): 61.

[186] X. Wang, Y. Zhou, L. Ning, J. Chen, H. Chen, and X. Li, “Knockdown of ANXA10 Induces Ferroptosis by Inhibiting Autophagy-mediated TFRC Degradation in Colorectal Cancer,” Cell Death & Disease 14, no. 9 (2023): 588.

[187] X. Hu, Y. He, Z. Han, et al., “PNO1 inhibits Autophagy-mediated Ferroptosis by GSH Metabolic Reprogramming in Hepatocellular Carcinoma,” Cell Death & Disease 13, no. 11 (2022): 1010.

[188] L. Ye, X. Wen, J. Qin, et al., “Metabolism-regulated Ferroptosis in Cancer Progression and Therapy,” Cell Death & Disease 15, no. 3 (2024): 196.

[189] B. Hassannia, B. Wiernicki, I. Ingold, et al., “Nano-targeted Induction of Dual Ferroptotic Mechanisms Eradicates High-risk Neuroblastoma,” The Journal of Clinical Investigation 128, no. 8 (2018): 3341–3355.

[190] Y. Wang, B. Tang, J. Zhu, et al., “Emerging Mechanisms and Targeted Therapy of Ferroptosis in Neurological Diseases and Neuro-oncology,” Int J Biol Sci 18, no. 10 (2022): 4260–4274.

[191] M. Y. Yao, T. Liu, L. Zhang, M. J. Wang, Y. Yang, and J. Gao, “Role of Ferroptosis in Neurological Diseases,” Neuroscience Letters 747 (2021): 135614.

[192] X. Qian, J. Zhang, Z. Gu, and Y. Chen, “Nanocatalysts-augmented Fenton Chemical Reaction for Nanocatalytic Tumor Therapy,” Biomaterials 211 (2019): 1–13.

[193] T. M. Seibt, B. Proneth, and M. Conrad, “Role of GPX4 in Ferroptosis and Its Pharmacological Implication,” Free Radic Biol Med 133 (2019): 144–152.

[194] Y. Motooka and S. Toyokuni, “Ferroptosis as Ultimate Target of Cancer Therapy,” Antioxidants & Redox Signaling 39, no. 1-3 (2023): 206–223.

[195] C. Li, X. Wu, C. Zheng, et al., “Nanotechnology-integrated Ferroptosis Inducers: A Sharp Sword Against Tumor Drug Resistance,” J Mater Chem B 10, no. 38 (2022): 7671–7693.

[196] Z. Xia and Y. Quan, “Effect of Tumor Microenvironment on Ferroptosis: Inhibition or Promotion,” Frontiers in Oncology 13 (2023): 1155511.

[197] X. Zhai, Y. Lin, L. Zhu, et al., “Ferroptosis in Cancer Immunity and Immunotherapy: Multifaceted Interplay and Clinical Implications,” Cytokine & Growth Factor Reviews 75 (2024): 101–109.

[198] R. Ali, H. Shao, and P. Varamini, “Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression Through TME Cell-Driven Populations,” Pharmaceutics 15, no. 1 (2022): 112.

[199] Z. Yu, Z. Mo, Y. Qiu, H. Lu, B. Zheng, and L. Liu, “Emerging Therapeutic Approaches Targeting Ferroptosis in Cancer: Focus on Immunotherapy and Nanotechnology,” Current Pharmaceutical Biotechnology 25, no. 15 (2024): 2012–2021.

[200] H. Yang, X. Yao, Y. Liu, X. Shen, M. Li, and Z. Luo, “Ferroptosis Nanomedicine: Clinical Challenges and Opportunities for Modulating Tumor Metabolic and Immunological Landscape,” ACS Nano 17, no. 16 (2023): 15328–15353.

[201] Q. Liu, Y. Zhao, H. Zhou, and C. Chen, “Ferroptosis: Challenges and Opportunities for Nanomaterials in Cancer Therapy,” Regenerative Biomaterials 10 (2023): rbad004.

[202] H. Zhou, Y. Cheng, Q. Huang, and J. Xiao, “Regulation of Ferroptosis by Nanotechnology for Enhanced Cancer Immunotherapy,” Expert Opin Drug Deliv 21, no. 6 (2024): 921–943.

[203] S. Guo, J. Feng, Z. Li, et al., “Improved Cancer Immunotherapy Strategies by Nanomedicine,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 15, no. 3 (2023): e1873.

[204] X. Meng, Y. Shen, H. Zhao, X. Lu, Z. Wang, and Y. Zhao, “Redox-manipulating Nanocarriers for Anticancer Drug Delivery: A Systematic Review,” J Nanobiotechnology 22, no. 1 (2024): 587.

[205] N. Dhas, R. Kudarha, R. Tiwari, et al., “Recent Advancements in Nanomaterial-mediated Ferroptosis-induced Cancer Therapy: Importance of Molecular Dynamics and Novel Strategies,” Life Sciences 346 (2024): 122629.

[206] K. Liu, L. Huang, S. Qi, et al., “Ferroptosis: The Entanglement Between Traditional Drugs and Nanodrugs in Tumor Therapy,” Adv Healthc Mater 12, no. 12 (2023): e2203085.

[207] Q. Song, Y. Zhang, H. Hu, et al., “Augment of Ferroptosis With Photothermal Enhanced Fenton Reaction and Glutathione Inhibition for Tumor Synergistic Nano-Catalytic Therapy,” Int J Nanomedicine 19 (2024): 11923–11940.

[208] L. Zhang, M. Qiu, R. Wang, et al., “Monitoring ROS Responsive Fe3O4-based Nanoparticle Mediated Ferroptosis and Immunotherapy via 129Xe MRI,” Angewandte Chemie (International Ed in English) 63, no. 22 (2024): e202403771.

[209] Y. Li, Y. Guo, K. Zhang, et al., “Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity,” Adv Sci (Weinh) 11, no. 3 (2024): e2306580.

[210] K. Li, K. Xu, Y. He, et al., “Oxygen Self-Generating Nanoreactor Mediated Ferroptosis Activation and Immunotherapy in Triple-Negative Breast Cancer,” ACS Nano 17, no. 5 (2023): 4667–4687.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.